D Reisman

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a
    Therese M Becker
    Westmead Institute for Cancer Research, University of Sydney, Westmead Millennium Institute and Westmead Hospital, Australia
    Mol Cancer 8:4. 2009
  2. ncbi The SWI/SNF complex and cancer
    D Reisman
    Department of Internal Medicine, University of Michigan College of Medicine, Ann Arbor, MI 48109 0686, USA
    Oncogene 28:1653-68. 2009
  3. ncbi The reversible epigenetic silencing of BRM: implications for clinical targeted therapy
    S Glaros
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan, Ann Arbor, MI, USA
    Oncogene 26:7058-66. 2007

Collaborators

  • C G Kleer
  • Therese M Becker
  • S Glaros
  • Graham J Mann
  • Monika Frausto
  • Lyndee L Scurr
  • Eve Diefenbach
  • Richard A Scolyer
  • Helen Rizos
  • Sebastian Haferkamp
  • Richard F Kefford
  • Menno K Dijkstra
  • C Muchardt
  • G M Cirrincione
  • C W Michael

Detail Information

Publications3

  1. ncbi The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a
    Therese M Becker
    Westmead Institute for Cancer Research, University of Sydney, Westmead Millennium Institute and Westmead Hospital, Australia
    Mol Cancer 8:4. 2009
    ..To identify such functions we conducted a yeast-two-hybrid screen for novel p16INK4a binding partners...
  2. ncbi The SWI/SNF complex and cancer
    D Reisman
    Department of Internal Medicine, University of Michigan College of Medicine, Ann Arbor, MI 48109 0686, USA
    Oncogene 28:1653-68. 2009
    ....
  3. ncbi The reversible epigenetic silencing of BRM: implications for clinical targeted therapy
    S Glaros
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan, Ann Arbor, MI, USA
    Oncogene 26:7058-66. 2007
    ..Thus, BRG1 and BRM are silenced by different mechanisms, and it may be possible to clinically target and reexpress BRM in a number of tumor types, potentially impacting tumor development...